Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Repros Jumps on Positive Drug Trials

By  +Follow September 17, 2013 8:01AM
Tickers Mentioned:

Shares in Texas pharma Repros Therapeutics, Inc. (RPRX) gapped up over 30 percent in early morning trading before settling into gains of just over 10 percent on heavy volume as the day wore on. The spike, driven by positive topline results from the most recent study on its drug Androxal® reported after close on Monday, pushed Repros stock to a new 52-week high.

Positive results for Androxal

Androxal is being developed for men of reproductive age with low testosterone due to secondary hypogonadism, which is also associated with obesity and could be among the most common causes of low testosterone. Repros reported that Andorxal met both co-primary endpoints in its second pivotal study, with 81 percent of subjects using the drug experiencing normalized testosterone and no 24-hour average testosterone levels outside of normal ranges. Androxal, which is in a class similar to Sanofi’s (SNY) Clomid®, could receive a strong share of the testosterone replacement therapy (TRT) market because it could also help preserve male fertility while being administered orally, making it significantly more convenient than testosterone replacement injections.  

Possible Sale

Brean Capital initiated coverage of Repros in July of this year, calling it a buy and setting a price target of $32. At the time, analyst Jonathan Aschoff said “Its lead compound Androxal is being evaluated in a Phase 3 program for secondary hypogonadism with results in 4Q13 and 2Q14, which in our view would be key investment catalysts, and we project Androxal launch in mid-2015.” Now, Brean is citing these positive results as a reason for optimism, as well as reports that management may have interest in selling the company. Brean estimated the sell-price potentially reaching $40 a share, in the event that the sale goes down.

In addition to Andorxal, Repros currently has female reproductive drug Proellex® in the pipeline, intended for use in uterine fibroids and endometriosis. “The vaginal formulation of Proellex (Proellex-V) will enter Phase 2b in 2H13 for uterine fibroids with an NDA submission expected in 2016. All compounds are protected by U.S. patents," said Aschoff in July.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for RPRX
24 Oct 14 11:05:01
@redacre I think it's an over-simplification of a more complex situation. He did get an SPA for 301 and 302 $RPRX
The Flash
24 Oct 14 10:23:03
$RPRX Looks like shorts about to lose control on this one. Very stealthy covers going on imo.
Smarter Analyst
24 Oct 14 07:52:26
$RPRX Brean Capital Maintains Buy On Repros Therapeutics Following Management Meetings http://t.co/OnahDfWFTp
24 Oct 14 07:46:41
Out of $RPRX for $250 gain.
24 Oct 14 07:35:56
$RPRX going
24 Oct 14 07:25:01
$RPRX on the move
24 Oct 14 07:14:40
RT @micheleciani: $OXGN $RPRX weak in the last days, could move stronger in the next ones, i expect $MNOV like moves here
Antonio Costa
24 Oct 14 06:46:54
$RPRX perks.....still holding...
24 Oct 14 06:12:03
With Androxal head to head studies available, the EMEA path seems highly plausible $RPRX
24 Oct 14 05:21:16
The EMEA regulatory path for Androxal is likely to be much more straight forward based on recent EU TRTs conclusions $RPRX
24 Oct 14 05:19:18
$RPRX meeting with the MPA in Sweden today to make its regulatory case in Europe
Michele Ciani
24 Oct 14 04:57:02
$OXGN $RPRX weak in the last days, could move stronger in the next ones, i expect $MNOV like moves here
23 Oct 14 22:04:03
During this #Ebola outbreak, $RPRX investors will also want to buy $SMED. They handle medical and hazardous waste http://t.co/vTV3wPBONo
23 Oct 14 14:30:48
RPRX 6.22 Stock Charts $RPRX Repros Therapeutics Inc. (NASDAQ) Last Updated: 10/23/2014 16:30:48 RPRX Stock Ch http://t.co/Mcq8OMdRgw
23 Oct 14 13:04:41
$RPRX overall option implied volatility of 158 is above its 26-week average of 93
23 Oct 14 13:04:30
$RPRX volatility elevated as shares trade near two-year low
Antonio Costa
23 Oct 14 12:49:19
"@TipRanks: 5* analyst Jonathan Aschoff from Brean Capital reiterated a BUY on $RPRX .Jonathan has a +10.4% avg rtrn http://t.co/2fVjZMOOXC"
Antonio Costa
23 Oct 14 12:46:54
$RPRX heating up into the close...
Stocks Pastor
23 Oct 14 12:45:55
It's ok to take profit on $RPRX. My intraday target from $6 is $6.25. Dip and rip scenario tomorrow
The Flash
23 Oct 14 12:40:00
$RPRX possible short squeeze here setting up off of double bottom. Reversing now.
Stocks Pastor
23 Oct 14 12:39:25
$RPRX never broke below $6 after my tweet. intraday target just achieved $6.25. Tomorrow $7-$7.50
Stocks Pastor
23 Oct 14 12:37:19
$RPRX at $6.24
Stocks Pastor
23 Oct 14 11:25:06
$RPRX still hanging there. Should be ready tomorrow
Stocks Pastor
23 Oct 14 10:49:34
Stocks Pastor
23 Oct 14 10:41:29
It's ok to watch $RPRX to see $6 held. Will make a good trade. $7-$7.50 possible
Stocks Pastor
23 Oct 14 10:38:54
$RPRX going now. Early stage.
Stocks Pastor
23 Oct 14 10:29:16
Very strong support for $RPRX at $6. $7 target
Stocks Pastor
23 Oct 14 10:15:58
$RPRX $7 target tomorrow if $6 holds on it. swing trade
Stocks Pastor
23 Oct 14 10:15:00
$RPRX support is $6. Let's see if that holds. $6.50 possible
Penny Stock Secret
23 Oct 14 09:47:22
The Hottest Way to Make Millions From Stock Market.Click HERE http://t.co/SVqoMkrw2z .. $AWRE $HOLI $RPRX
Michele Ciani
23 Oct 14 09:36:30
$RPRX Bought more here on weakness
Stephen Mason
23 Oct 14 09:28:46
$RPRX Building Position in low $6 range. Buying Dec$5 puts for protection. Also got Nov $5 calls. FDA Meeting 1st half of Nov
Stephen Mason
23 Oct 14 09:25:36
$RPRX Dec $10 Calls seeing a lot of volume. Playing follow the leader picked some up for .80
23 Oct 14 09:16:33
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $ANAC $ACTV $RPRX
Stocks News&Markets
23 Oct 14 08:51:08
$TBI down -11.73% today! Check out this trade http://t.co/zrPbQ96ROz I made 14% on $RPRX JOIN US LIVE: http://t.co/EQWvokRIdO
 Luke Murray
23 Oct 14 06:31:11
$RPRX in 6.40
Joe McCann
23 Oct 14 06:30:39
@markallan777 why only 12? $rprx is now not much further ahead if they are at all and have worse data look at where that cap has maxed at
Scalp Trades
23 Oct 14 06:26:41
http://t.co/qy0iEYfRE0 Day trade watchlist: $JAKK, $BDBD, $RPRX, $CYTX, $ACTG, $CAKE, $CTXS, $FTNT, $INFN, $IPCM, $YELP, $PLCM, $TSCO, $UVXY
23 Oct 14 05:29:08
RT @micheleciani: #biotech #buy #stocks $RNN $RPRX $OCRX $CYCC $KBIO $ECYT $IPCI $SPHS $LPDX $VSTM $AEZS $AGEN and others http://t.co/MyO7l…
Michele Ciani
23 Oct 14 04:59:00
#biotech #buy #stocks $RNN $RPRX $OCRX $CYCC $KBIO $ECYT $IPCI $SPHS $LPDX $VSTM $AEZS $AGEN and others http://t.co/MyO7lZcSqh
Michele Ciani
23 Oct 14 04:58:12
$RPRX creating a base from where come back higher. Patience will pay
23 Oct 14 00:44:39
Repros Therapeutics Inc (RPRX) 6.21 $RPRX Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amge http://t.co/jEkCs5IhlZ
23 Oct 14 00:22:18
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $ANAC $ACTV $RPRX
22 Oct 14 22:34:12
22 Oct 14 21:05:27
how to trade $HIMX $YHOO $YELP $KO $MCD $NQ $CREE $GOOGL $GOOG $IRBT $RPRX $OCN $ISRG $LL http://t.co/uTZpFW8a4K
lord of trading
22 Oct 14 18:30:11
Talk #Money http://t.co/aHmArax2Za #Trading #Fashion #Art #Traveling #Music $SCOK $SHPG $ESI $CMF $RPRX $HAS http://t.co/CGuG1Nvulk
Mike Robinson
22 Oct 14 15:27:12
RT @ACInvestorBlog: $RPRX Just out: Buy rating on Repros Therapeutics with a $41 price target. http://t.co/6AwnXeN6Yw
22 Oct 14 14:49:21
After Hours Advancers: $RGLS, $UIS, $ROYL, $SIX, $RPRX, $NLS, $IPWR, $GORO, $AKER, $SMCI, $PDCE, $SCMP, $IRBT, $IPG, $BRCM ......
22 Oct 14 13:42:57
$RPRX thats sum serious bagholdin!
22 Oct 14 12:32:25
@FonsieTrader ok which one is it? $RPRX or $RGLS
By  +Follow September 17, 2013 8:01AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.